Dossier assessment
Vibegron (overactive bladder) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Vibegron (overactive bladder) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Vibegron (overactive bladder) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome
Result of dossier assessment:
- Patients ≥ 65 years: hint of a minor added benefit
- Patients < 65 years: added benefit not proven
Project details
- Project no.
- A25-39
- Commission
- Commission awarded on 03.03.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-39